About Macrophage Therapeutics

About company

Macrophage Therapeutics (MT) is developing novel immuno-oncology and targeted anti-inflammatory therapeutics based on its proprietary Activated Macrophage targeting platform. MT is leveraging its unique CD206 receptor-based delivery system to deliver proven therapeutics in a more precise and targeted fashion. With binding affinities 10,000X today’s best antibodies MT’s approach eliminates off-target toxicity and increases the efficacy of proven therapeutic agents. MT’s CD206 targeting platform is already clinically established and being used in an FDA/EMEA approved radiopharmaceutical.